855
Participants
Start Date
September 12, 2022
Primary Completion Date
August 5, 2026
Study Completion Date
August 5, 2026
Inclisiran
Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Vienna
Novartis Investigative Site, Vienna
Novartis Investigative Site, Geneva
Novartis Investigative Site, Fribourg
Novartis Investigative Site, Linz
Novartis Investigative Site, Basel
Novartis Investigative Site, Olten
Novartis Investigative Site, Sankt Veit im Pongau
Novartis Investigative Site, Feldkirch
Novartis Investigative Site, Dubai
Novartis Investigative Site, Zurich
Novartis Investigative Site, Graz
Novartis Investigative Site, Zurich
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Riyadh
Novartis Investigative Site, Jeddah
Novartis Investigative Site, Tabuk
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Kuala Lumpur
Novartis Investigative Site, Shenzhen
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Holon
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Abu Dhabi
Novartis Investigative Site, Al Ain City
Novartis Investigative Site, Dubai
Novartis Investigative Site, High Wycombe
Novartis Investigative Site, Louth
Novartis Investigative Site, Sunderland
Novartis Investigative Site, Belfast
Novartis Investigative Site, Bromwich
Novartis Investigative Site, Burton-on-Trent
Novartis Investigative Site, Cardiff
Novartis Investigative Site, Hull
Novartis Investigative Site, Lancaster
Novartis Investigative Site, Liverpool
Novartis Investigative Site, London
Novartis Investigative Site, Middlesex
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY